Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL

January 9th 2025

Supriya Gupta, MD, details pros/cons with different BTK inhibitors and promising combination therapies in CLL, as well as how liso-cel is affecting care.

ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR

January 9th 2025

The phase 3 ARES trial of MaaT013 in third-line GI-aGVHD met its primary end point of GI-ORR at day 28.

Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma

January 9th 2025

Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.

FDA Releases Draft Guidance on Tissue Biopsies in Clinical Trials

January 8th 2025

The FDA has issued a draft guidance offering recommendations regarding tissue biopsies in clinical trials for pediatric and adult patients.

Multidisciplinary Collaboration Is Crucial in Managing Ocular Toxicities of Mirvetuximab Soravtansine in Gynecologic Tumors

January 8th 2025

Rebecca Arend, MD, and Kathryn Lyle, CRNP, discuss their approach to managing ocular and other treatment-related toxicities associated with mirvetuximab soravtansine.

Invikafusp Alfa Receives FDA Fast Track Designation for TMB-High CRC

January 8th 2025

Phase 1 data showed the potential for invikafusp alfa as a precision cancer immunotherapeutic agent in solid tumors after exposure to PD-(L)1 therapy.

China’s NMPA Approves Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer

January 8th 2025

Enfortumab vedotin-efjv plus has received NMPA approval for patients with locally advanced or metastatic urothelial cancer.

FDA Issues Draft Guidance for Accelerated Approval Confirmatory Clinical Trials

January 8th 2025

The FDA released a draft guidance document detailing their interpretation of when a confirmatory clinical trial for an accelerated approval is underway.

Retifanlimab Emerges as Potential New SOC in Advanced SCAC

January 7th 2025

Sheela Rao, MBBS, MD, FRCP, discusses data from the phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab plus chemotherapy vs chemotherapy in advanced SCAC.

Novel BTK Degrader NX-5948 Yields High Response Rates in Pretreated CLL/SLL

January 7th 2025

Nirav N. Shah, MD, MSHP, details how BTK degraders could fill an unmet need in pretreated CLL/SLL and highlights promising data seen with NX-5948.

Imetelstat Plus Ruxolitinib Demonstrates Tolerable Safety Profile in Myelofibrosis

January 6th 2025

Imetelstat plus ruxolitinib showed early tolerability and efficacy in patients with intermediate and high-risk myelofibrosis.

Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification

January 2nd 2025

China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.

European Commission Approves Lazertinib Plus Amivantamab in First-Line EGFR-Mutated NSCLC

January 2nd 2025

The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.

FDA Approval Sought for Dordaviprone in Recurrent H3K27M+ Diffuse Glioma

January 2nd 2025

A NDA has been submitted to the FDA seeking the approval of dordaviprone for recurrent H3K27M-mutant diffuse glioma.

Working on the Frontlines of a Revolution in Multiple Myeloma Care

December 30th 2024

A Mayo Clinic “lifer” who did not consider medicine as a career path until his later teenage years grew into a powerhouse who touched nearly every aspect of the multiple myeloma field, and he continues to push the boundaries of what is possible.

Transparency and Consolidation Issues Hamper 340B Program in Cancer Care

December 30th 2024

Since it's implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and other diseases expanded access to affordable medications by selling drugs at discounted prices to eligible centers.

Preparation is Key to Tackle the Transition from Fellow to Attending Physician

December 29th 2024

A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.

Community Practice Training During Fellowship Often Falls Short

December 28th 2024

A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.

National Fellows Forum Highlights Future Research Directions in HGSOC and HCC

December 26th 2024

Oncology fellows gathered at the OncLive National Fellows Forum to share research findings, network, and join panels on career development strategies.

Pilot Program Improves Palliative Care Training for Hematology/Oncology Fellows

December 25th 2024

The director of the Hematology/Oncology Fellowship Training Program at Fox Chase Cancer Center discusses palliative care training for hematology/oncology fellows and highlights a pilot study aimed at improving this area of training.